Tian An Medicare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Tian An Medicare şirketinin toplam hissedar öz sermayesi HK$1.9B ve toplam borcu HK$804.2M olup, bu da borç-öz sermaye oranını 42.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$3.5B ve HK$1.6B dir. Tian An Medicare 'in FAVÖK'ü HK$83.2M faiz karşılama oranı 43.7 dur. Şirketin HK$831.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

42.6%

Borç/özkaynak oranı

HK$804.16m

Borç

Faiz karşılama oranı	43.7x
Nakit	HK$830.97m
Eşitlik	HK$1.89b
Toplam yükümlülükler	HK$1.59b
Toplam varlıklar	HK$3.48b

Son finansal sağlık güncellemeleri

Recent updates

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Feb 02

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Oct 26

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

Sep 30

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

Dec 10

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

Apr 08

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Feb 14

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

Dec 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 383 'nin kısa vadeli varlıkları ( HK$1.3B ) kısa vadeli yükümlülüklerini ( HK$996.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 383 şirketinin kısa vadeli varlıkları ( HK$1.3B ) uzun vadeli yükümlülüklerini ( HK$595.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 383 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 383 'nin borç/öz sermaye oranı son 5 yılda 44.8% seviyesinden 42.6% seviyesine düştü.

Borç Kapsamı: 383 'nin borcu işletme nakit akışı ( 28.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 383 'in borcuna ilişkin faiz ödemeleri EBIT ( 43.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Tian An Medicare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

Recent updates

New minor risk - Market cap size

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 in 1H 2023)

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 loss in 1H 2023)

Tian An Medicare Limited to Report Q4, 2024 Results on Aug 02, 2024

Upcoming dividend of HK$0.01 per share

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & Healthcare Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 02 August 2024

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024

China Medical & HealthCare Group Limited to Report Fiscal Year 2023 Final Results on Mar 15, 2024

New minor risk - Market cap size

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes

China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees

Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million.

China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees

First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.061 loss in 1H 2022)

New major risk - Revenue and earnings growth

China Medical & HealthCare Group Limited to Report Second Half, 2023 Results on Aug 18, 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

Full year 2022 earnings released: HK$0.17 loss per share (vs HK$0.19 loss in FY 2021)

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

Less than half of directors are independent

China Medical & Healthcare Group Limited Announces Executive Changes

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.003 loss per share (vs HK$0.005 loss in 1H 2021)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

Less than half of directors are independent

Full year 2021 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2020)

China Medical & HealthCare Group Limited, Annual General Meeting, Jun 01, 2022

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Executive Director has left the company

Non-Executive Director has left the company

Chairman Liye Zhou has left the company

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

China Medical & HealthCare Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

China Medical & Healthcare Group Limited Appoints Lai Hin Wing Henry Stephen as Non-Executive Director, Effective November 11, 2020

First half earnings released

China Medical & HealthCare Group Limited to Report 18 Months Period Ending Dec 31, 2019 Results on Mar 30, 2020

China Medical & HealthCare Group Limited to Report Second Half, 2020 Results on Aug 27, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin